Awada, Ahmad

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 807

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., et al. (2019) · npj Breast Cancer

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 685

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies

Perdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M. (2017) · Cancers

Cancer-related Molecular PathwaysCell death mechanisms and regulation

Cited by 126

Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients

Bulitta, J. B., Zhao, P., Arnold, R. D., Kessler, D. R., Daifuku, R., Pratt, J., Luciano, G., Hanauske, A.-R., Gelderblom, H., Awada, A., et al. (2009) · Cancer Chemotherapy and Pharmacology

Cancer Treatment and PharmacologyNanoparticle-Based Drug Delivery

Cited by 47

Learning from the “tsunami” of immune checkpoint inhibitors in 2015

Kourie, H. R., Awada, G., & Awada, A. H. (2016) · Critical Reviews in Oncology/Hematology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 42